Nomanesit (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium and sumatriptan succinate, the active ingredients in Nomanesit, are an NSAID and a 5‑HT1B/1D receptor agonist presented as oral tablets for oral use. The combination is indicated for the acute treatment of migraine attacks in adults, providing both anti‑inflammatory and vasoconstrictive actions for rapid symptom relief.

GNH USA supplies Nomanesit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and offering secure, temperature‑controlled logistics for global distribution.

Nomanesit combines an NSAID and a triptan to address migraine pathophysiology. - Migraine with aura: aborts attacks and reduces associated symptoms such as nausea and photophobia. - Migraine without aura: provides rapid headache relief and improves functional ability. - Acute migraine attacks: delivers dual action to lessen pain intensity and duration.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Dry mouth: reduced salivation. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia. - Severe allergic reaction (anaphylaxis): swelling, difficulty breathing. - Serotonin syndrome: agitation, hyperthermia, tremor. - Cardiovascular events: stroke or myocardial infarction. - Severe liver injury: jaundice, elevated enzymes. - Stevens‑Johnson syndrome: severe skin rash.

Before prescribing Nomanesit, clinicians should evaluate patient‑specific risk factors. - Assess cardiovascular risk: patients with coronary artery disease should be evaluated before use. - Avoid in uncontrolled hypertension: monitor blood pressure closely. - Use caution with other serotonergic agents: risk of serotonin syndrome. - Avoid in patients with known hypersensitivity to NSAIDs or triptans. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Nomanesit may interact with several drug classes; monitoring is essential. Major Interactions (Avoid): - Concomitant use with MAO inhibitors: risk of serotonin syndrome. - Combined with other triptans or ergot derivatives: increased vasoconstriction risk. - Use with potent CYP3A4 inhibitors: may raise sumatriptan plasma levels. - Concurrent anticoagulants/antiplatelet agents: heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Co‑administration with SSRIs or SNRIs: monitor for serotonin syndrome. - Use with other NSAIDs: increased gastrointestinal toxicity. - Combination with antihypertensives: may reduce antihypertensive effect.